Karuna Therapeutics to Participate in the ICR Conference 2021
Karuna Therapeutics (NASDAQ: KRTX) announced that Andrew Miller, Ph.D., COO and founder, will speak at the ICR Conference 2021 on January 14, 2021, at 3:15 p.m. EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Andrew Miller, Ph.D., chief operating officer and founder, will participate in a fireside chat at the ICR Conference 2021 on Thursday, January 14, 2021 at 3:15 p.m. EST.
A live webcast of the presentation will be available on the Investor Relations page of Karuna’s website at investors.karunatx.com. A replay of the webcast will also be archived for up to 90 days on Karuna’s website following the conference.
About Karuna Therapeutics
Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by these severe and disabling disorders. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples’ lives. For more information, please visit www.karunatx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005423/en/